首页> 外文期刊>BMC Ophthalmology >Intraoperative intravitreal triamcinolone acetonide injection for prevention of postoperative inflammation and complications after phacoemulsification in patients with uveitic cataract
【24h】

Intraoperative intravitreal triamcinolone acetonide injection for prevention of postoperative inflammation and complications after phacoemulsification in patients with uveitic cataract

机译:术中玻璃体内纤维素型乙烯酮酮酮注射预防Uveitic白内障患者术中乳化术后术后炎症和并发症

获取原文
       

摘要

We aimed to evaluate the efficacy and safety of phacoemulsification with intravitreal 3?mg triamcinolone acetonide injection in preventing postoperative inflammation and complications in patients with non-infectious anterior uveitis and panuveitis complicated cataract. In this retrospective cohort study, 140 uveitic cataract patients who received phacoemulsification and intraocular lens implantation in Shanxi Eye hospital from January 2018 to January 2020 were reviewed. The IVTA group (51 eyes of 41 patients) received intravitreal injection of 3?mg triamcinolone acetonide (TA) at the end of surgery, and the control group (51 eyes of 41 patients) without injection matched by propensity score matching were enrolled. Outcome measures were best corrected visual acuity (BCVA), anterior chamber inflammation, intraocular pressure, corneal endothelial cell density, central macular thickness and complications within 3?months follow-up. The degree of postoperative anterior chamber inflammation in the IVTA group was lighter than that in the control group (P 0.05). Two of 51 eyes (3.9%) in the IVTA group and 8 of 51 eyes (15.7%) in the control group had recurrence of uveitis; 6 of 45 eyes (13.3%) in the control group developed cystoid macular edema but none in the IVTA group; 11 of 51 eyes (21.6%) in the IVTA group and 22 of 51 eyes (43.1%) in the control group developed posterior synechiae postoperatively. Intraoperative Intravitreal injection of 3?mg TA is an effective and safe adjunctive therapy for preventing postoperative inflammation and complications to promote early recovery for anterior uveitis or panuveitis complicated cataract patients following phacoemulsification. This retrospective cohort study was in accordance with the tenets of the Helsinki Declaration and was approved by the Shanxi Eye Hospital Ethics Committee. Written informed consent was obtained from all participants for their clinical records to be used in this study.
机译:我们的旨在评估术治术中术治疗术治疗术治疗术治疗非传染前葡萄膜炎和恐慌炎复杂性白内障术后术后术治疗术治疗术治疗术后炎症的疗效和安全性。在这项回顾性队列中,2018年1月至2020年1月接受了山西眼医院沉默乳化和眼内晶状体植入的140名USITAL患者。 IVTA组(51只4例患者)在手术结束时接受玻璃体内注射3?Mg Triaminolone乙酸钠(TA),并注册了通过倾向得分匹配的无注射匹配的对照组(41名患者的51只眼)。结果措施是最佳矫正视力(BCVA),前腔炎症,眼内压,角膜内皮细胞密度,中央黄斑厚度和3个月内的并发症。 IVTA组术后前房炎症程度比对照组更轻(P 0.05)。 IVTA组中的两个中有两个(3.9%)和对照组的51只眼(15.7%)的葡萄膜炎复发;对照组中6只45只眼(13.3%)显影了囊状黄斑水肿,但在IVTA组中没有; IVTA组中的11个中的11个(21.6%)和对照组中的22只(43.1%)在术后术后展开了后稳态。术中玻璃体内注射3?Mg Ta是一种有效和安全的辅助治疗,用于预防术后炎症和并发症,以促进前蜂鸣中的前葡萄膜炎或恐慌性白内障患者的早期恢复。这种回顾性队列研究符合赫尔辛基宣言的原则,并得到山西眼科医院道德委员会的批准。书面知情同意书获取了所有参与者,以便在本研究中使用的临床记录。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号